Compare · NTRA vs TLSI
NTRA vs TLSI
Side-by-side comparison of Natera Inc. (NTRA) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $48.53B, about 156.7x TLSI ($309.7M).
- NTRA has been more active in the news (16 items in the past 4 weeks vs 3 for TLSI).
- NTRA has more recent analyst coverage (25 ratings vs 6 for TLSI).
- Company
- Natera Inc.
- TriSalus Life Sciences Inc.
- Price
- -
- -
- Market cap
- $48.53B
- $309.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2021
- News (4w)
- 16
- 3
- Recent ratings
- 25
- 6
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest NTRA
- CO-FOUNDER Sheena Jonathan sold $1,951,942 worth of shares (6,000 units at $325.32) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 230,464 units (SEC Form 4)
- Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
- CO-FOUNDER Sheena Jonathan sold $2,888,325 worth of shares (9,150 units at $315.66) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 236,464 units (SEC Form 4)
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $641,800 worth of shares (2,000 units at $320.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Natera Reports Second Quarter 2026 Financial Results
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $79,057 worth of shares (295 units at $267.99) as part of a pre-agreed trading plan, decreasing direct ownership by 0.16% to 183,774 units (SEC Form 4) (for tax liability)
- CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $216,030 worth of shares (795 units at $271.74) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 51,637 units (SEC Form 4) (withholding obligation)
Latest TLSI
- SEC Form 10-Q filed by TriSalus Life Sciences Inc.
- TriSalus Life Sciences Reports Second Quarter 2026 Results
- TriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
- TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.
- Chief Financial Officer Patience David covered exercise/tax liability with 14,650 shares, decreasing direct ownership by 5% to 261,107 units (SEC Form 4) (tax liability)
- CEO and President Szela Mary T was granted 3,990 shares, increasing direct ownership by 0.37% to 1,077,683 units (SEC Form 4)
- Szela Mary T increased direct ownership by 101% to 1,023,826 units (SEC Form 5)
- Chief Commercial Officer Marshak Richard was granted 561 shares, increasing direct ownership by 0.44% to 128,319 units (SEC Form 4)